Phio Pharmaceuticals CORP DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Phio Pharmaceuticals Corp. issued a proxy supplement to correct a scrivener's error regarding the total number of shares reserved for its Long Term Incentive Plan.
NASDAQ
Phio Pharmaceuticals Corp. announced its 2025 Annual Stockholder Meeting to be held virtually on September 11, 2025, to vote on director elections, auditor ratification, an increase in the long-term incentive plan shares, and executive compensation.
NASDAQ
Phio Pharmaceuticals Corp. is seeking shareholder approval for key corporate governance matters, including the election of directors and a significant increase in its equity incentive plan, while facing a 'going concern' warning from its auditors.
NASDAQ
DEFA14A: Phio Pharmaceuticals Corp. to Hold Annual Stockholder Meeting, Proposes Reverse Stock Split
Phio Pharmaceuticals Corp. will hold its annual stockholder meeting on June 17, 2024, to vote on director elections, auditor ratification, a potential reverse stock split, and an amendment to the long-term incentive plan.
NASDAQ
DEF 14A: Phio Pharmaceuticals Seeks Stockholder Approval for Reverse Stock Split and Incentive Plan Expansion
Phio Pharmaceuticals is asking stockholders to vote on proposals including a reverse stock split to maintain Nasdaq listing and an increase in shares available under its long-term incentive plan.